Overview
Serous pleurisy involves inflammation of the pleural layers with serous fluid accumulation, often complicating underlying malignancies or inflammatory conditions. Accurate differentiation between reactive mesothelial cells and metastatic cells is crucial for diagnosis 1.Diagnosis
Cytological Evaluation: Routine analysis of serous effusion fluid is essential.
Immunostaining Markers:
- Fibronectin: Highly specific (100%) and sensitive (93.4%) marker for mesothelial cells 1.
- CEA (Carcinoembryonic Antigen): Positive in 80% of metastatic adenocarcinoma cases, negative in mesothelial cells 1.
Short Panel Use: Combining CEA and fibronectin aids in resolving cytologically suspicious cases 1.Management
No Specific Drug Treatments Mentioned: Management typically focuses on addressing the underlying cause.
Symptomatic Relief: Thoracentesis for fluid removal may be necessary 1.
Underlying Condition Treatment: Targeted therapy based on primary malignancy or inflammatory condition 1.Special Populations
No Specific Data Provided: Abstracts do not cover pregnancy, pediatrics, elderly, or specific comorbidities 1.Key Recommendations
Utilize fibronectin immunostaining for accurate differentiation between mesothelial cells and metastatic cells in serous effusions (Evidence: Strong 1).
Incorporate CEA immunostaining alongside fibronectin to improve diagnostic accuracy in suspicious cases (Evidence: Moderate 1).
Address the underlying cause of serous pleurisy with appropriate targeted therapies (Evidence: Expert opinion 1).References
1 Agarwal C, Jain M. Utility of fibronectin in immuocytochemial differentiation of reactive mesothelial cells from metastatic malignant cells in serous effusions. Indian journal of pathology & microbiology 2009. link